26 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp07552 | macrocyclic pyridoheptapeptide derivative 1a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 15.329 ± 0.672 μM |
| dbacp07553 | macrocyclic pyridoheptapeptide derivative 1a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 6.615 ± 0.353 μM |
| dbacp07554 | macrocyclic pyridoheptapeptide derivative 1b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 10.904 ± 0.534 μM |
| dbacp07555 | macrocyclic pyridoheptapeptide derivative 1b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.724 ± 0.474 μM |
| dbacp07556 | macrocyclic pyridoheptapeptide derivative 1c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 34.894 ± 1.273 μM |
| dbacp07557 | macrocyclic pyridoheptapeptide derivative 1c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 17.011 ± 0.965 μM |
| dbacp07558 | macrocyclic pyridoheptapeptide derivative 2a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 17.513 ± 0.876 μM |
| dbacp07559 | macrocyclic pyridoheptapeptide derivative 2b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 20.697 ± 0.974 μM |
| dbacp07560 | macrocyclic pyridoheptapeptide derivative 2b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 18.681 ± 0.988 μM |
| dbacp07561 | macrocyclic pyridoheptapeptide derivative 2c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 24.943 ± 1.082 μM |
| dbacp07562 | macrocyclic pyridoheptapeptide derivative 2c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 19.318 ± 1.057 μM |
| dbacp07563 | macrocyclic pyridoheptapeptide derivative 3a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 10.316 ± 0.546 μM |
| dbacp07564 | macrocyclic pyridoheptapeptide derivative 3a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.063 ± 0.863 μM |
| dbacp07565 | macrocyclic pyridoheptapeptide derivative 3b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 9.911 ± 0.491 μM |
| dbacp07566 | macrocyclic pyridoheptapeptide derivative 3b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.66 ± 0.792 μM |
| dbacp07567 | macrocyclic pyridoheptapeptide derivative 3c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 22.864 ± 0.992 μM |
| dbacp07568 | macrocyclic pyridoheptapeptide derivative 3c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 16.957 ± 1.161 μM |
| dbacp07569 | macrocyclic pyridoheptapeptide derivative 4a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 9.304 ± 0.536 μM |
| dbacp07570 | macrocyclic pyridoheptapeptide derivative 4a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 7.31 ± 0.595 μM |
| dbacp07571 | macrocyclic pyridoheptapeptide derivative 4b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 9.188 ± 0.545 μM |
| dbacp07572 | macrocyclic pyridoheptapeptide derivative 4b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 7.166 ± 0.892 μM |
| dbacp07573 | macrocyclic pyridoheptapeptide derivative 4c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | MCF-7 | Breast Cancer | IC50 = 19.552 ± 1.032 μM |
| dbacp07574 | macrocyclic pyridoheptapeptide derivative 4c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.631 ± 0.932 μM |
| dbacp07575 | macrocyclic pyridoheptapeptide derivative 5a | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 7.117 ± 0.790 μM |
| dbacp07576 | macrocyclic pyridoheptapeptide derivative 5b | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 7.088 ± 0.784 μM |
| dbacp07577 | macrocyclic pyridoheptapeptide derivative 5c | Structure given in Scheme 1 | Synthetic | Macrocyclic peptides disrupt cancer growth | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.568 ± 1.139 μM |